Mark Lievonen is President of Sanofi Pasteur Limited, the Canadian vaccine division of Sanofi, which he joined in 1983. Under his leadership, Sanofi Pasteur has become a billion-dollar enterprise in Canada, manufacturing over 50 million doses of vaccines for both domestic and international markets.>
A veteran of the industry for over 30 years, Lievonen began his career in finance and rose through Sanofi Pasteur’s ranks, guiding the company through a number of significant milestones and initiatives. He notably spearheaded a cancer vaccine program in 1997 and supported the key launch of a five-component pertussis vaccine, which is still widely used today. Working closely with the provincial and federal governments, Lievonen has led the site through several major contracts and investments, including the opening of the $100-million, state-of-the-art research and development facility in Toronto.
Lievonen holds a BBA in accounting and an MBA in finance and marketing from the Schulich School of Business, York University. He is a chartered accountant and received his designation while working with PricewaterhouseCoopers.
He is the recipient of many awards including a Queen’s Golden Jubilee Medallion, the Queen’s Diamond Jubilee Medal and was named a Member of the Order of Canada, in recognition of his outstanding achievements, leadership and unwavering commitment to the pursuit of sustainable healthcare.